Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 94

Similar articles for PubMed (Select 24772319)

1.

Safety and continuity of second- and third-line therapy with paclitaxel or irinotecan for advanced and recurrent gastric cancer.

Kimura M, Usami E, Kanematsu T, Iwai M, Yoshimura T, Mori H, Sugiyama T, Teramachi H.

Mol Clin Oncol. 2014 May;2(3):466-472. Epub 2014 Feb 14.

2.

Third-line chemotherapy with paclitaxel, irinotecan hydrochloride and cisplatin for recurrent gastric cancer: a case report.

Takahashi N, Suzuki H, Iwabuchi S, Yamazaki Y, Yanaga K.

Hepatogastroenterology. 2005 Jan-Feb;52(61):326-8.

PMID:
15783061
4.

Phase II study on the combination of irinotecan plus cisplatin as a second-line therapy in patients with advanced or recurrent gastric cancer.

Rino Y, Yukawa N, Sato T, Oshima T, Tanabe H, Yamamoto Y, Matsukawa H, Shiraishi R, Imada T, Masuda M.

Mol Clin Oncol. 2013 Jul;1(4):749-752. Epub 2013 May 9.

5.
6.

Medical therapy of advanced malignant epithelial tumours of the ovary.

Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A.

Forum (Genova). 2000 Oct-Dec;10(4):323-32. Review.

PMID:
11535983
7.

Retrospective evaluation of sequential outpatient chemotherapy for advanced gastric cancer.

Satoh S, Kawashima K, Matsumoto S, Hasegawa S, Okabe H, Nomura A, Yoshibayashi H, Watanabe G, Nagayama S, Fukushima M, Sakai Y.

Chemotherapy. 2007;53(3):226-32. Epub 2007 Mar 14.

PMID:
17356271
8.

Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to fluorouracil, irinotecan, and cisplatin.

Shimoyama R, Yasui H, Boku N, Onozawa Y, Hironaka S, Fukutomi A, Yamazaki K, Taku K, Kojima T, Machida N, Todaka A, Tomita H, Sakamoto T, Tsushima T.

Gastric Cancer. 2009;12(4):206-11. doi: 10.1007/s10120-009-0524-9. Epub 2010 Jan 5.

PMID:
20047125
9.

Feasibility study of biweekly CPT-11 plus CDDP for S-1- and paclitaxel-refractory, metastatic gastric cancer.

Yoshida T, Yoshikawa T, Tsuburaya A, Kobayashi O, Hasegawa S, Osaragi T, Sairenji M.

Anticancer Res. 2006 Mar-Apr;26(2B):1595-8.

11.

A retrospective comparison of docetaxel and paclitaxel for patients with advanced or recurrent esophageal cancer who previously received platinum-based chemotherapy.

Mizota A, Shitara K, Kondo C, Nomura M, Yokota T, Takahari D, Ura T, Muro K.

Oncology. 2011;81(3-4):237-42. doi: 10.1159/000334057. Epub 2011 Nov 17.

PMID:
22094594
12.

Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial.

Nishikawa K, Fujitani K, Inagaki H, Akamaru Y, Tokunaga S, Takagi M, Tamura S, Sugimoto N, Shigematsu T, Yoshikawa T, Ishiguro T, Nakamura M, Morita S, Miyashita Y, Tsuburaya A, Sakamoto J, Tsujinaka T.

Eur J Cancer. 2015 May;51(7):808-16. doi: 10.1016/j.ejca.2015.02.009. Epub 2015 Mar 18.

13.

Availability of irinotecan in a second-line setting confers survival benefit to patients with advanced gastric cancer refractory to fluoropyrimidine-based regimens.

Oba M, Chin K, Kawazoe Y, Takagi K, Ogura M, Shinozaki E, Suenaga M, Matsusaka S, Mizunuma N, Hatake K.

Oncol Lett. 2011 Mar;2(2):247-251. Epub 2011 Jan 20.

14.

[A case of paclitaxel-resistant recurrent gastric cancer responsive to S-1 plus docetaxel].

Nishikawa K, Iwase K, Aono T, Yoshida H, Nomura M, Tamagawa H, Matsuda C, Deguchi T, Kawada J, Higashi S, Deguchi K, Noguchi Y, Okumura Y, Nomura M, Fushimi H, Takagi M, Fukui A, Fujitani K, Endo S, Tanaka Y.

Gan To Kagaku Ryoho. 2013 Nov;40(12):2259-61. Japanese.

PMID:
24394078
15.

Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the gastrointestinal oncology group of the Tokyo cooperative oncology group, TCOG GC-0501 trial.

Koizumi W, Akiya T, Sato A, Yamaguchi K, Sakuyama T, Nakayama N, Tanabe S, Higuchi K, Sasaki T, Sekikawa T; Tokyo Cooperative Oncology Group (TCOG GI Group).

Jpn J Clin Oncol. 2009 Nov;39(11):713-9. doi: 10.1093/jjco/hyp099. Epub 2009 Oct 6.

16.

[A case of recurrent gastric cancer successfully treated by a combination of CPT-11 and CDDP as the third-line chemotherapy].

Tonooka T, Yoshioka S, Wakatsuki K, Kataoka M, Miyazawa K, Oeda Y.

Gan To Kagaku Ryoho. 2012 Nov;39(12):2354-6. Japanese.

PMID:
23268075
17.

Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial.

Hironaka S, Ueda S, Yasui H, Nishina T, Tsuda M, Tsumura T, Sugimoto N, Shimodaira H, Tokunaga S, Moriwaki T, Esaki T, Nagase M, Fujitani K, Yamaguchi K, Ura T, Hamamoto Y, Morita S, Okamoto I, Boku N, Hyodo I.

J Clin Oncol. 2013 Dec 10;31(35):4438-44. doi: 10.1200/JCO.2012.48.5805. Epub 2013 Nov 4.

18.

Irinotecan monotherapy offers advantage over combination therapy with irinotecan plus cisplatin in second-line setting for treatment of advanced gastric cancer following failure of fluoropyrimidine-based regimens.

Oba M, Chin K, Kawazoe Y, Takagi K, Ogura M, Shinozaki E, Suenaga M, Matsusaka S, Mizunuma N, Hatake K.

Oncol Lett. 2011 Mar;2(2):241-245. Epub 2011 Jan 20.

19.

A phase II study of biweekly mitomycin C and irinotecan combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group (JCOG0109-DI Trial).

Hamaguchi T, Shirao K, Ohtsu A, Hyodo I, Arai Y, Takiuchi H, Fujii H, Yoshida M, Saito H, Denda T, Koizumi W, Iwase H, Boku N; Gastrointestinal Oncology Study Group of Japan Clinical Oncology Group.

Gastric Cancer. 2011 Aug;14(3):226-33. doi: 10.1007/s10120-011-0030-8. Epub 2011 Apr 19.

PMID:
21503598
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk